Unlike previous reviews that have examined and discussed resistin’s role in isolated diseases, this study focuses exclusively on diabetes-induced models and clinical evidence in patients with T2D, providing a more targeted perspective on its pathophysiological mechanisms and potential as a clinical biomarker. This evidence concerns the gene RETN and diabetes mellitus.